How Does Kevzara Work? Mechanism of Action Explained in Plain English

If you've been prescribed Kevzara (sarilumab), you might be wondering: "How exactly does this drug work?" Understanding Kevzara's mechanism of action doesn't require a medical degree—it's a surprisingly logical story about a protein called IL-6, the immune system gone wrong, and how scientists designed a molecule to specifically neutralize that problem.

What Is IL-6 and Why Does It Matter?

Interleukin-6 (IL-6) is a protein—called a cytokine—that your immune system produces as part of its communication network. Under normal circumstances, IL-6 is helpful: it signals the immune system to respond to infections and tissue damage, and it plays a role in regulating fever, liver function, and immune cell development.

In people with rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR), the immune system produces far too much IL-6. This overproduction drives chronic, excessive inflammation that attacks the body's own tissues—particularly the joints in RA, and the muscles and connective tissues in PMR. Elevated IL-6 is closely correlated with disease activity, joint destruction, fatigue, anemia, and elevated inflammatory markers like CRP and ESR.

How Does Kevzara Block IL-6?

IL-6 doesn't cause inflammation directly. To do its work, IL-6 first has to bind to a receptor on the surface of cells—called the IL-6 receptor (IL-6Rα). Think of IL-6 as a key, and the IL-6 receptor as the lock. When the key fits the lock, it triggers a cascade of inflammatory signals inside the cell.

Kevzara (sarilumab) is a monoclonal antibody—a laboratory-engineered protein—specifically designed to bind to the IL-6 receptor and block it. By occupying the IL-6 receptor, Kevzara physically prevents IL-6 from binding to it. If the key can't reach the lock, the inflammatory cascade can't start.

Specifically, sarilumab binds to both the soluble and membrane-bound forms of the IL-6 receptor. Some IL-6 receptors are embedded in cell membranes; others float freely in the bloodstream. Kevzara blocks both—which gives it broad IL-6 inhibition.

What Makes Kevzara a "Fully Human" Antibody?

Kevzara is classified as a fully human immunoglobulin G1 (IgG1) monoclonal antibody. This is an important technical distinction: fully human antibodies are engineered to look identical to antibodies that a human immune system would naturally produce. This design minimizes the chance of the body mounting an immune reaction against the drug itself (called immunogenicity), which was a problem with earlier, partially-mouse-derived antibody medications.

Sarilumab was developed using Regeneron's proprietary VelocImmune® technology—a platform that uses genetically engineered mice with humanized immune systems to produce optimized fully human antibodies. The resulting molecule has an approximate molecular weight of 150 kDa and is manufactured using recombinant DNA technology in Chinese Hamster Ovary cell cultures.

What Happens in Your Body When You Inject Kevzara?

After Kevzara is injected under your skin, it is slowly absorbed into the bloodstream. The antibody then circulates throughout your body and binds to IL-6 receptors, blocking the inflammatory signaling that was driving your symptoms. This is why patients often notice that their CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate)—two blood markers of inflammation—drop significantly when they start Kevzara.

In RA patients, the apparent volume of distribution of sarilumab at steady state is about 7.3 liters—meaning it distributes broadly throughout the body. With every-2-week dosing, sarilumab reaches steady-state concentrations after the first few doses, providing consistent IL-6 blockade throughout the treatment cycle.

How Is Kevzara Different From Other Biologics?

Several biologics are used for RA, but they work by different mechanisms:

TNF inhibitors (adalimumab, etanercept, infliximab) — Block tumor necrosis factor (TNF), a different inflammatory protein. Many patients respond well to TNF inhibitors, but some with inadequate response to TNF inhibitors do well on Kevzara.

Tocilizumab (Actemra) — Also an IL-6 receptor blocker, like Kevzara. Clinical trials show similar efficacy between tocilizumab and sarilumab. A key difference: tocilizumab now has biosimilars available; sarilumab does not.

Abatacept (Orencia) — Blocks T-cell activation. A different checkpoint in the immune cascade than IL-6.

JAK inhibitors (baricitinib, upadacitinib) — Block intracellular signaling pathways (JAK-STAT) that are activated by multiple cytokines including IL-6. Oral tablets rather than injections.

Comparing these options is important when choosing therapy. For more detail on alternatives, see our article Alternatives to Kevzara. If you're having trouble finding or affording Kevzara, medfinder can help you locate pharmacies near you that carry it.